news
Hosted by Simon Wentworth · news · EN-US · 38 episodes
The Pharma Letter Podcast provides in-depth discussion and analysis focused on key trends, companies and events in the pharmaceutical and biotech industries. Our guests come from a broad array of sectors and business functions, from early stage research in biopharmaceuticals, to patient engagement and marketing, supply chain management and life sciences investing. Podcasts are typically 20-30 minutes in length and are released approximately once every two weeks.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Public web form
Booking probability
30%
Guest openness
Selective
Sign up to generate a grounded pitch for The Pharma Letter Podcast.
Signup to Generate a PitchThe Pharma Letter Podcast provides in-depth discussion and analysis focused on key trends, companies and events in the pharmaceutical and biotech industries. Our guests come from a broad array of sectors and business functions, from early stage research in biopharmaceuticals, to patient engagement and marketing, supply chain management and life sciences investing.
The Pharma Letter Podcast is hosted by Simon Wentworth. The show has published 38 episodes to date.
Recent episodes include "Orbis CEO on turning biologics into pills" (19 August 2026, 16 minutes), "BenevolentAI CEO on the future of AI-led medicine" (6 May 2026, 30 minutes), and "ConcertAI CEO Eron Kelly on Big Tech's role in biotech" (13 March 2026, 18 minutes).
The Pharma Letter Podcast publishes roughly every few months, with episodes averaging 20 minutes across 38 episodes.
Booking probability for The Pharma Letter Podcast is 30%, and the host is rated Selective on guests. The Pharma Letter Podcast requires a Pod Score of 80 or higher. The Pharma Letter Podcast's contact route on record: public web form.
The strongest fits for The Pharma Letter Podcast are Pharmaceuticals and Scientific Research & Development. The Pharma Letter Podcast has a news audience.
Simon Wentworth hosts The Pharma Letter Podcast, a news show with 38 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #39
This week on The Pharma Letter Podcast, we’re joined by Morten Graugaard, chief executive of Orbis Medicines: a Danish-Swiss biotech working to turn biologic-like medicines into oral therapies. Founded out of Novo...
Episode #38
This week on The Pharma Letter Podcast, we’re joined by Kenneth Mulvany, founder and executive chair of BenevolentAI: one of the UK’s earliest and most high-profile attempts to apply machine learning to drug discovery...
Episode #37
This week on The Pharma Letter Podcast, we’re joined by Eron Kelly, chief executive of ConcertAI: a company applying artificial intelligence to accelerate oncology research and clinical development. ConcertAI sits at...
Episode #36
This week on the Podcast, we are joined by Dr Amr Hanbali. During Blood Cancer Awareness Month, Guy Martin, news editor at The Pharma Letter, sat down with Dr Hanbali to discuss his experiences treating patients with...
Episode #35
This week on The Pharma Letter Podcast, we’re joined by Marina Udier, chief executive of Nouscom — a biotech company developing cancer vaccines. Founded in 2015, the firm is working on cancer vaccines that use a viral...
Episode #34
This week on The Pharma Letter Podcast, we’re joined by Howard Fillit, co-founder and chief science officer at the Alzheimer’s Drug Discovery Foundation (ADDF). As the FDA approval of anti-amyloid drugs like lecanemab...
Episode #33
This week on The Pharma Letter Podcast, we’re joined by Quin Wills, co-founder and chief scientific officer of UK biotech Ochre Bio. A physician-scientist with a background in genomics and computational biology, Quin...
Episode #32
This week on The Pharma Letter Podcast, we are joined by Tony Clarke, senior VP of IT digital operations at ICON (Nasdaq: ICLR). As a leader in digital transformation within clinical research, Tony has been at the...
Episode #31
In this week’s podcast, we welcome Iddo Peleg, CEO and co-founder of Yonalink, who provides insights into the current and future state of the clinical trial industry. As we move headlong into 2025, a year that appears...
Episode #30
In this episode, we’ll take a look at the role of Japanese pharmaceutical groups in the UK, with Jackie Davis, general manager at Astellas Pharma. Tokyo-headquartered Astellas (TYO: 4503) has developed a strong...
Episode #29
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. We are joined by Yanay Ofran, chief executive and founder of...
Episode #28
This week we’re focusing on an area of clinical research that has been of great interest for a number of years, that is NASH, also known as MASH. It’s a high area of unmet medical need, with over 20 million diagnosed...
Episode #27
This week we are speaking with the chief executive of British drug development company Ellipses Pharma. Founded in 2018 to create new cancer therapies, the firm is following a unique multimodal approach to clinical...
Episode #26
In the world of outsourced clinical research, ICON is a big fish in a pond full of other increasingly big fish. In this episode of The Pharma Letter Podcast, we chat with the company’s chief commercial officer, George...
Episode #24
With an Accelerated nod for Aduhelm (aducanumab) and now full approval for Leqembi (lecanemab) in the USA, Biogen (Nasdaq: BIIB) and Eisai (TYO: 4523) have overturned decades of failure in Alzheimer’s. But at the annual...
Episode #23
In the runup to the annual meeting of the Alzheimer’s Association, this week we are speaking with Michael Irizarry, deputy chief clinical officer at Eisai US. At the event in July, there will be plenty to discuss, with...
Episode #22
Set against a backdrop of foundering confidence in biotech stocks, the success of some companies incubated by Massachusetts-based Flagship Pioneering has been remarkable. Flagship has invested billions of dollars...
Episode #21
A draft of the European Commission’s ongoing review of pharmaceutical legislation has leaked, prompting a bitterly-worded reaction from drugmakers, which accuse legislators of “sabotaging” the industry. There is no...
Episode #20
This week on The Pharma Letter Podcast, we are joined by Galapagos (Euronext: GLPG) chief executive Paul Stoffels. After an illustrious career as chief scientific officer at Johnson & Johnson (NYSE: JNJ), Dr Stoffels is...
Episode #19
The outcome of the recent midterm elections in the USA surprised many by returning a Democrat-led Senate, preventing Republicans from gaining control of the next Congress. Analysts, having expected a stronger showing...
Recent guests on The Pharma Letter Podcast. Study who booked and why before you pitch.
PitchCentric classifies The Pharma Letter Podcast under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ